Skip header and navigation

Refine By

68 records – page 1 of 7.

[A comparative evaluation of the efficacy of immunocorrection in children with bronchial asthma living in ecologically contrasted regions]

https://arctichealth.org/en/permalink/ahliterature15907
Source
Lik Sprava. 1995 Jul-Aug;(7-8):59-61
Publication Type
Article
Author
S V Trishina
V N Zorin
Iu F Babin
S V Trishin
A V Ruban
V V Ruban
V S Skorobatskii
Source
Lik Sprava. 1995 Jul-Aug;(7-8):59-61
Language
Russian
Publication Type
Article
Keywords
Adjuvants, Immunologic - administration & dosage
Adolescent
Aerosols
Air Pollution - adverse effects
Asthma - drug therapy - immunology
Child
Child, Preschool
Comparative Study
Ecology
English Abstract
Humans
T-Lymphocytes - drug effects - immunology
Thymus Hormones - administration & dosage
Ukraine
Abstract
Overall 50 children suffering from infectious-allergic bronchial asthma who live in ecologically contrasting regions were examined. Those children residing in unfavourable, in terms of ecological conditions, regions demonstrated diminution of the peripheral blood T-lymphocytes together with a decrease in their functional activity as well as in the activity of interleukin 2. It is in this group of children that immunomodulating effect of thymalin is less apparent. It is suggested that the relevant immune correction in such cases might be achieved through repeated courses of treatment with immunomodulating agents and rehabilitation of patients in favourable ecological conditions together with prescribing of other immunostimulators of selective action in respect of the T-link of the immunity system.
PubMed ID
8846376 View in PubMed
Less detail

[A deficient T-cell count and its elimination during the treatment and prevention of infections].

https://arctichealth.org/en/permalink/ahliterature214429
Source
Zh Mikrobiol Epidemiol Immunobiol. 1995 Sep-Oct;(5):68-71
Publication Type
Article
Author
A M Zemskov
V M Zemskov
V A Platonova
E D Chertok
A M Tupkalova
A T Vysotskaia
T A Zemskova
A A Degtiarev
S E Furgal
Iu A Evstratov
Source
Zh Mikrobiol Epidemiol Immunobiol. 1995 Sep-Oct;(5):68-71
Language
Russian
Publication Type
Article
Keywords
Acute Disease
Adjuvants, Immunologic - administration & dosage
Adolescent
Adult
Bacterial Infections - drug therapy - immunology - prevention & control
Biological Markers
Carrier State - drug therapy - immunology - prevention & control
Child
Child, Preschool
Chronic Disease
Female
Humans
Infant
Lymphocyte Count
Male
Middle Aged
Military Personnel
Nucleic Acids - administration & dosage
Russia
T-Lymphocytes - immunology
Abstract
The results of the study of the parameters of the immune system in persons suffering from frequent infections, bacteriocarriers and persons with nonspecific infections are presented. The study revealed that T-cell deficiency of the 2nd and 3rd degrees could be regarded as the universal marker of decreased immune reactiveness. Sodium nucleinate was found to be capable of stimulating the T-cell element of immunity and antibody formation, which made it possible to achieve a considerable decrease in morbidity rate. Sodium nucleinate was shown to be highly effective in the prophylaxis of acute respiratory viral infections, carrier state and in the sanitation of purulent foci of infection.
PubMed ID
8525738 View in PubMed
Less detail

[Adjuvant systemic chemotherapy in colon cancer]

https://arctichealth.org/en/permalink/ahliterature22753
Source
Ugeskr Laeger. 1996 Feb 26;158(9):1222-7
Publication Type
Article
Date
Feb-26-1996
Author
H H Raskov
Author Affiliation
Kirurgisk gastroenterologisk afdeling D, Amtssygehuset i Gentofte.
Source
Ugeskr Laeger. 1996 Feb 26;158(9):1222-7
Date
Feb-26-1996
Language
Danish
Publication Type
Article
Keywords
Adjuvants, Immunologic - administration & dosage
Antimetabolites, Antineoplastic - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Chemotherapy, Adjuvant
Colonic Neoplasms - drug therapy - mortality - surgery
English Abstract
Fluorouracil - administration & dosage
Humans
Leucovorin - administration & dosage
Levamisole - administration & dosage
Prognosis
Abstract
The prognosis for patients with cancer of the colon is dubious. An intendedly curative colon resection is performed in two-thirds of these patients, but half of them will subsequently die from metastatic disease. Randomized trials of adjuvant therapy with fluorouracil in combination with levamisole or leucovorin have shown significant benefit in terms of increased disease-free survival and overall survival. In 1990 adjuvant treatment was recommended as routine therapy in high risk patients in USA. A number of European countries are routinely treating high risk patients with Dukes' C coloncarcinoma. The recommendations are based on results from several cooperative trials reviewed in this article. Treatment related toxicity accelerates with increasing age but was acceptable in the reviewed trials. Adjuvant therapy is widely accepted as an important supplement to surgery in high risk patients. A Conference on the results and experiences now available should take place in the near future in order to establish a national consensus on adjuvant chemotherapy in Denmark. Patients with resected Dukes' C coloncarcinoma should receive adjuvant chemotherapy including 5-fluorouracil and leucovorin. Randomized trials are needed to establish the most effective regimens but "no-treatment" controls are no longer ethically acceptable.
PubMed ID
8644427 View in PubMed
Less detail

Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study.

https://arctichealth.org/en/permalink/ahliterature18415
Source
Eur Urol. 2003 Jun;43(6):637-45
Publication Type
Article
Date
Jun-2003
Author
Eero Kaasinen
Hans Wijkström
Per Uno Malmström
Sverker Hellsten
Milos Duchek
Oddvar Mestad
Erkki Rintala
Author Affiliation
Department of Surgery, Hyvinkää Hospital, Sairaalakatu 1, FIN-05850 Hyvinkää, Finland. eero.kaasinen@hus.fi
Source
Eur Urol. 2003 Jun;43(6):637-45
Date
Jun-2003
Language
English
Publication Type
Article
Keywords
Adjuvants, Immunologic - administration & dosage
Administration, Intravesical
Aged
Antibiotics, Antineoplastic - administration & dosage - therapeutic use
BCG Vaccine - administration & dosage
Bladder Neoplasms - drug therapy - therapy
Carcinoma in Situ - drug therapy - therapy
Combined Modality Therapy
Disease-Free Survival
Female
Humans
Male
Mitomycin - administration & dosage - therapeutic use
Neoplasm Recurrence, Local - prevention & control
Research Support, Non-U.S. Gov't
Scandinavia
Abstract
OBJECTIVES: To evaluate whether, in patients with carcinoma in situ (CIS) of the urinary bladder, alternating instillation therapy with mitomycin C (MMC) and bacillus Calmette-Guerin (BCG) was more effective and less toxic than conventional BCG monotherapy. METHODS: Patients were stratified prospectively for primary, secondary, and concomitant CIS and randomized to one of two regimens. Patients in the alternating group received six weekly intravesical instillations of MMC 40 mg, followed by alternating monthly instillations of BCG 120 mg and MMC for one year. In the monotherapy group, only BCG was instilled on the same schedule. RESULTS: Of 323 enrolled patients, 304 were eligible for analysis. After an overall median follow-up of 56 months, the Kaplan-Meier disease-free estimate for BCG monotherapy was significantly better than that for alternating therapy (p=0.03; log rank test). Risk for progression appeared lower in the BCG monotherapy group (p=0.07), but no differences existed in survival. Besides the regimen, CIS category also predicted outcome to some extent. BCG monotherapy caused significantly more local side-effects and premature cessation of instillation treatment than did the alternating therapy. However, no differences were observed in the number of serious side-effects. CONCLUSION: One-year BCG monotherapy was more effective than the alternating therapy for reducing recurrence and compared well with the best regimens reported from substantially smaller series. The alternating therapy was better tolerated.
PubMed ID
12767365 View in PubMed
Less detail

[Application of systemic enzyme therapy in combined treatment of patients with pulmonary cancer and malignant thymoma]

https://arctichealth.org/en/permalink/ahliterature19900
Source
Klin Khir. 2000 Jun;(6):17-9
Publication Type
Article
Date
Jun-2000
Author
V L Hanul
I I Smolanka
O V Ponomar'ova
Source
Klin Khir. 2000 Jun;(6):17-9
Date
Jun-2000
Language
Ukrainian
Publication Type
Article
Keywords
Adjuvants, Immunologic - administration & dosage - therapeutic use
Chymotrypsin
Combined Modality Therapy
Drug Combinations
English Abstract
Humans
Lung Neoplasms - complications - therapy
Pancreatic Extracts - administration & dosage - therapeutic use
Papain - administration & dosage - therapeutic use
Thymoma - complications - therapy
Thymus Extracts - administration & dosage - therapeutic use
Thymus Neoplasms - complications - therapy
Trypsin
Abstract
The systemic enzymotherapy using Wobe-Mugos E in the combined treatment of 32 patients with pulmonary cancer and of 21 patients with malignant thymoma was applied. After the chemotherapy and radiotherapy conduction the reduction of the postoperative septic-purulent complications, the pneumofibrosis occurrence prophylaxis was noted.
PubMed ID
11288269 View in PubMed
Less detail

AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland.

https://arctichealth.org/en/permalink/ahliterature125558
Source
PLoS One. 2012;7(3):e33536
Publication Type
Article
Date
2012
Author
Hanna Nohynek
Jukka Jokinen
Markku Partinen
Outi Vaarala
Turkka Kirjavainen
Jonas Sundman
Sari-Leena Himanen
Christer Hublin
Ilkka Julkunen
Päivi Olsén
Outi Saarenpää-Heikkilä
Terhi Kilpi
Author Affiliation
Department of Vaccines and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland. hanna.nohynek@thl.fi
Source
PLoS One. 2012;7(3):e33536
Date
2012
Language
English
Publication Type
Article
Keywords
Adjuvants, Immunologic - administration & dosage
Adolescent
Adult
Aged
Aged, 80 and over
Child
Child, Preschool
Cohort Studies
Databases, Factual
Finland - epidemiology
Humans
Incidence
Influenza A Virus, H1N1 Subtype
Influenza Vaccines - adverse effects - immunology
Middle Aged
Narcolepsy - epidemiology - etiology
Retrospective Studies
Vaccination
Young Adult
Abstract
Narcolepsy is a chronic sleep disorder with strong genetic predisposition causing excessive daytime sleepiness and cataplexy. A sudden increase in childhood narcolepsy was observed in Finland soon after pandemic influenza epidemic and vaccination with ASO3-adjuvanted Pandemrix. No increase was observed in other age groups.
Retrospective cohort study. From January 1, 2009 to December 31, 2010 we retrospectively followed the cohort of all children living in Finland and born from January 1991 through December 2005. Vaccination data of the whole population was obtained from primary health care databases. All new cases with assigned ICD-10 code of narcolepsy were identified and the medical records reviewed by two experts to classify the diagnosis of narcolepsy according to the Brighton collaboration criteria. Onset of narcolepsy was defined as the first documented contact to health care because of excessive daytime sleepiness. The primary follow-up period was restricted to August 15, 2010, the day before media attention on post-vaccination narcolepsy started.
Vaccination coverage in the cohort was 75%. Of the 67 confirmed cases of narcolepsy, 46 vaccinated and 7 unvaccinated were included in the primary analysis. The incidence of narcolepsy was 9.0 in the vaccinated as compared to 0.7/100,000 person years in the unvaccinated individuals, the rate ratio being 12.7 (95% confidence interval 6.1-30.8). The vaccine-attributable risk of developing narcolepsy was 1:16,000 vaccinated 4 to 19-year-olds (95% confidence interval 1:13,000-1:21,000).
Pandemrix vaccine contributed to the onset of narcolepsy among those 4 to 19 years old during the pandemic influenza in 2009-2010 in Finland. Further studies are needed to determine whether this observation exists in other populations and to elucidate potential underlying immunological mechanism. The role of the adjuvant in particular warrants further research before drawing conclusions about the use of adjuvanted pandemic vaccines in the future.
Notes
Cites: J Clin Invest. 2001 Oct;108(8):1097-10411602615
Cites: PLoS One. 2012;7(3):e3372322470463
Cites: Proc Soc Exp Biol Med. 1976 Mar;151(3):615-22815915
Cites: N Engl J Med. 1989 Apr 6;320(14):881-62648146
Cites: Sleep. 1997 Nov;20(11):1012-209456467
Cites: Clin Microbiol Rev. 2006 Jan;19(1):80-9416418524
Cites: Lancet. 2007 Feb 10;369(9560):499-51117292770
Cites: Sleep. 2007 Jan;30(1):13-2617310860
Cites: Diabetologia. 2007 Jul;50(7):1393-40017492426
Cites: Neuroepidemiology. 2007;29(3-4):185-9218043003
Cites: Sleep Med Rev. 2008 Apr;12(2):95-10718291691
Cites: Arthritis Rheum. 2008 May;58(5):1343-5318438855
Cites: Diabetes Res Clin Pract. 2008 Nov;82(2):247-5518804305
Cites: Nat Rev Immunol. 2009 Apr;9(4):246-5819319143
Cites: Sleep. 2009 Aug;32(8):979-8319725248
Cites: Med Hypotheses. 2010 Mar;74(3):433-4219932569
Cites: Brain. 2010 May;133(Pt 5):1300-1120403960
Cites: Vaccine. 2010 Aug 16;28(36):5837-4420600478
Cites: Nat Genet. 2010 Sep;42(9):786-920711174
Cites: Sleep. 2010 Nov;33(11):1428-3021102981
Cites: Nucleic Acids Res. 2011 Jan;39(Database issue):D913-921062830
Cites: Ann Neurol. 2011 Sep;70(3):410-721866560
Cites: J Autoimmun. 2003 Aug;21(1):1-912892730
PubMed ID
22470453 View in PubMed
Less detail

[A treatment modality for children with heart and rheumatic diseases who are frequently ill with respiratory infections]

https://arctichealth.org/en/permalink/ahliterature13962
Source
Lik Sprava. 2002;(2):56-8
Publication Type
Article
Date
2002
Author
Iu V Marushko
V M Son'kin
T V Marushko
L M Kucheruk
Source
Lik Sprava. 2002;(2):56-8
Date
2002
Language
Ukrainian
Publication Type
Article
Keywords
Adjuvants, Immunologic - administration & dosage - therapeutic use
Adolescent
Arthritis, Rheumatoid - complications - therapy
Child
Child, Preschool
English Abstract
Female
Heart Diseases - complications - therapy
Humans
Immunotherapy
Male
Respiratory Tract Infections - complications - therapy
Abstract
Our objective in this study was to carry out an immunological assessment of use of immunomodulating agents in a complex therapy of those children with poor health who are always ailing and present with cardiorheumatological pathology. A way for prevention of aggravation of cardiorheumatological pathology is submitted, involving the use of bronchomunal and narine according to the developed treatment regimen.
PubMed ID
12073263 View in PubMed
Less detail

Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus.

https://arctichealth.org/en/permalink/ahliterature130111
Source
Arthritis Care Res (Hoboken). 2011 Nov;63(11):1517-20
Publication Type
Article
Date
Nov-2011
Author
Murray B Urowitz
Anoja Anton
Dominique Ibanez
Dafna D Gladman
Author Affiliation
University of Toronto Lupus Clinic and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, Ontario, Canada.
Source
Arthritis Care Res (Hoboken). 2011 Nov;63(11):1517-20
Date
Nov-2011
Language
English
Publication Type
Article
Keywords
Adjuvants, Immunologic - administration & dosage - adverse effects
Adult
Autoantibodies - blood
Biological Markers - blood
Female
Humans
Influenza A Virus, H1N1 Subtype - immunology
Influenza Vaccines - adverse effects - immunology
Influenza, Human - immunology - prevention & control - virology
Logistic Models
Lupus Erythematosus, Systemic - diagnosis - immunology
Male
Middle Aged
Ontario
Patient Selection
Risk assessment
Risk factors
Time Factors
Vaccination - adverse effects
Abstract
It has been reported that influenza vaccination increases autoantibody production and/or disease activity in a significant proportion of patients with systemic lupus erythematosus (SLE). During the recent H1N1 epidemic, we investigated whether the use of adjuvant- and nonadjuvant-containing H1N1 vaccine induced increased autoantibody production in patients with SLE.
Patients with SLE who received H1N1 vaccination and had a battery of 9 autoantibodies tested before and 1 and 3 months after vaccination were included. Antibodies tested included rheumatoid factor (nephelometry), antinuclear antibody (immunofluorescence), anti-DNA (Farr), anti-RNP, anti-Sm, anti-Ro, anti-La, anti-Scl-70, and anti-Jo-1 (enzyme-linked immunosorbent assay). Patients were evaluated by standard protocol, including items necessary to calculate the Systemic Lupus Erythematosus Disease Activity Index 2000 and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. Descriptive statistics and McNemar's test were performed to evaluate change in antibody positivity. Multivariate logistic regression was performed to adjust for repeated measures in the comparisons of autoantibodies over visits and vaccine types.
One hundred three patients (94 women, 9 men) with a mean ± SD age at vaccination of 43.9 ± 15.2 years and a mean ± SD disease duration of 14.2 ± 11.0 years were included. Fifty-one patients received adjuvant and 52 received nonadjuvant vaccines. Antibody testing was performed a mean of 1.9 months prior to the vaccination. The first postvaccination sample was taken a mean of 1 month after vaccination and the second a mean of 3.5 months after vaccination. The percentage of patients with changes in antibodies following vaccination was not statistically significant for most antibodies. After adjusting for the number of tests performed, none of the associations was significant.
H1N1 vaccination (both adjuvant and nonadjuvant) did not increase the levels of autoantibodies in patients with SLE.
PubMed ID
22034113 View in PubMed
Less detail

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.

https://arctichealth.org/en/permalink/ahliterature88763
Source
J Natl Cancer Inst. 2009 Jun 16;101(12):869-77
Publication Type
Article
Date
Jun-16-2009
Author
Bouwhuis Marna G
Suciu Stefan
Collette Sandra
Aamdal Steinar
Kruit Wim H
Bastholt Lars
Stierner Ulrika
Salès François
Patel Poulam
Punt Cornelis J A
Hernberg Micaela
Spatz Alain
ten Hagen Timo L M
Hansson Johan
Eggermont Alexander M M
Author Affiliation
Department of Surgical Oncology, Erasmus University MC-Daniel den Hoed Cancer Center, 301 Groene Hilledijk, Rotterdam, the Netherlands.
Source
J Natl Cancer Inst. 2009 Jun 16;101(12):869-77
Date
Jun-16-2009
Language
English
Publication Type
Article
Keywords
Adjuvants, Immunologic - administration & dosage - therapeutic use
Adult
Aged
Antibodies, Anticardiolipin - blood
Antibodies, Antinuclear - blood
Autoantibodies - blood
Bias (epidemiology)
Confounding Factors (Epidemiology)
Disease-Free Survival
Enzyme-Linked Immunosorbent Assay
Female
Humans
Interferon-alpha - administration & dosage - therapeutic use
Male
Melanoma - drug therapy - immunology
Middle Aged
Odds Ratio
Proportional Hazards Models
Randomized Controlled Trials as Topic
Skin Neoplasms - drug therapy - immunology
Time Factors
Abstract
BACKGROUND: Appearance of autoantibodies and clinical manifestations of autoimmunity in melanoma patients treated with adjuvant interferon (IFN)-alpha2b was reported to be associated with improved prognosis. We assessed the association of the appearance of autoantibodies after initiation of treatment with recurrence-free interval in two randomized trials that compared intermediate doses of IFN with observation for the treatment of melanoma patients. METHODS: Serum levels of anticardiolipin, antithyroglobulin, and antinuclear antibodies were determined using enzyme-linked immunosorbent assays in 187 and 356 patients in the European Organization for Research and Treatment of Cancer (EORTC) 18952 and Nordic IFN trials, respectively, immediately before and up to 3 years after random assignment. The association of the presence of at least one of the three autoantibodies with risk of recurrence was assessed by three Cox models in patients negative for all three autoantibodies at baseline (125 from the EORTC 18952 trial and 230 from the Nordic IFN trial): 1) a model that considered appearance of autoantibodies as a time-independent variable, 2) one that considered a patient autoantibody positive once a positive test for an autoantibody was obtained, and 3) a model in which the status of the patient was defined by the most recent autoantibody test. All statistical tests were two-sided. RESULTS: When treated as a time-independent variable (model 1), appearance of autoantibodies was associated with improved relapse-free interval in both trials (EORTC 18952, hazard ratio [HR] = 0.41, 95% confidence interval [CI] = 0.25 to 0.68, P
PubMed ID
19509353 View in PubMed
Less detail

[Betaferon--first experience of application in treatment of multiple sclerosis in Russia].

https://arctichealth.org/en/permalink/ahliterature209709
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(12):24-7
Publication Type
Article
Date
1997
Author
I A Zavalishin
N N Iakhno
T D Zhuchenko
A S Niiazbekova
Source
Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(12):24-7
Date
1997
Language
Russian
Publication Type
Article
Keywords
Adjuvants, Immunologic - administration & dosage - therapeutic use
Adult
Disease Progression
Drug Administration Schedule
Drug Evaluation
Follow-Up Studies
Humans
Injections, Subcutaneous
Interferon-beta - administration & dosage - therapeutic use
Magnetic Resonance Imaging
Middle Aged
Multiple Sclerosis - diagnosis - immunology - therapy
Recurrence
Russia
Safety
T-Lymphocytes - drug effects - immunology
Treatment Outcome
Abstract
32 patients (21-55 years old) with multiple sclerosis (MS) were treated. Remittent form of the disease was observed in 24 patients, secondary progressive one--in 8 individuals; the degree of disability was characterised as scores 0-3 (the first group) and scores 5-6 (the second one) according to scale EDSS. Betaferon was administered subcutaneously in the dose of 8 MIU every other day during the period from several months to 1 year and more. Improvement of the state was observed in 5 patients with remittent form, stop of the development of disease (absence of either aggravations or signs of MS progression) was found in 26 cases (21 with remittent form, 4 with secondary progressive form). The conclusion was made: betaferon cannot cure but can stop progression of the disease. Indications and contraindications for betaferon therapy were established and recommendations were given concerning regimen of the treatment prophylaxis and therapy of side-effects.
PubMed ID
9591060 View in PubMed
Less detail

68 records – page 1 of 7.